CN Patent

CN111265532A — 取代氨基丙酸酯类化合物在治疗2019-nCoV感染中的应用

Assigned to Institute of Pharmacology and Toxicology of AMMS · Expires 2020-06-12 · 6y expired

What this patent protects

本发明涉及式I所示取代氨基丙酸酯类化合物，及其药物上可接受的盐和/或其溶剂化物和/或其水合物，及含有此化合物的药物组合物，用于治疗2019新型冠状病毒(2019‑nCoV)引起的感染。

USPTO Abstract

本发明涉及式I所示取代氨基丙酸酯类化合物，及其药物上可接受的盐和/或其溶剂化物和/或其水合物，及含有此化合物的药物组合物，用于治疗2019新型冠状病毒(2019‑nCoV)引起的感染。

Drugs covered by this patent

Patent Metadata

Patent number
CN111265532A
Jurisdiction
CN
Classification
—
Expires
2020-06-12
Drug substance claim
No
Drug product claim
No
Assignee
Institute of Pharmacology and Toxicology of AMMS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.